Home » Authors » Anette Breindl

Articles by Anette Breindl

Blinatumomab Gets 100% Response Rate Before MTD

Aug. 20, 2008

By Anette Breindl

Current Heparin Production Method Called Vulnerable

Aug. 19, 2008

By Anette Breindl

Blinatumomab Gets 100% Response Rate Before MTD

Aug. 15, 2008

By Anette Breindl

Immune Suppressant Can Stimulate Immune System

Aug. 14, 2008

By Anette Breindl

RNAi Broadens its Horizons, Takes Aim at HIV, Cholesterol

Aug. 12, 2008

By Anette Breindl

Sense-Antisense Pair Feeds Each Other, Amyloid Plaques

Aug. 11, 2008

By Anette Breindl

NewCo News: Sea Lane Biotechnologies Describes New 'Surrobodies'

Aug. 7, 2008

By Anette Breindl

Postpartum Depression Tied to Lack of Receptor Subunit

Aug. 5, 2008

By Anette Breindl

iPS Cells from ALS Patients May Help Research, Therapy

Aug. 1, 2008

By Anette Breindl

Slowly, Schizophrenia Begins to Yield its Genomic Secrets

July 31, 2008

By Anette Breindl

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Viva in vivo! At EHA, in vivo CAR T data continues to impress
BioWorld
Treatment with first-generation CAR T cells regularly sent patients to the intensive care unit. Now, investigators are envisioning a future where CAR T treatment...